Abstract
An oral monolithic osmotically controlled delivery system for nifedipine using asymmetric membrane technology was developed and evaluated. Unlike conventional osmotic systems, which require laser drilling, this system releases the drug in a controlled manner from asymmetric membrane coated core tablets. Asymmetric membrane is formed by dry process with phase inversion technology process using cellulose acetate as the coating material. Higher water influx of this membrane aids in delivery of nifedipine, which is highly water insoluble with low osmotic pressure. The porous structure of the membrane was confirmed by scanning electron microscopy. Influence of different osmotic agents on drug release was evaluated. In vitro release studies showed that as concentration of osmotic agents was increased, the drug release was also enhanced. Drug release from the developed monolithic system was independent of external agitation and pH of dissolution media. Comparative in vitro release data was obtained using different types of coating membranes like controlled porosity membrane and dense coating membrane with mechanically drilled orifice. Osmotic pressure generated in the system was determined using freezing point osmometer. The osmotic pressure developed was found to be linearly proportional to time and concentration of osmotic agent.
Similar content being viewed by others
References
Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release. 1995;35:1–21.
Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987–91.
Garg S, Verma RK, Krishna DM. Formulation aspects in the development of osmotically controlled oral delivery systems. J Control Release. 2002;79:7–27.
Liu L, Khang G, Rhee JM, Lee HB. Monolithic osmotic tablet system for nifedipine delivery. J Control Release. 2000;67:309–22.
Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-membrane tablet coatings for osmotic drug delivery. J Control Release. 1995;35:127–36.
Chidlaw MB, Herbig SN, Korsmeyer RW. Osmotic drug delivery from asymmetric membrane film-coated dosage forms. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker; 2000. p. 751–85.
Fiesen E, Hagen TA. Preformulation. In: Lachman L, Lieberman HA, Kanig JL, editors. Theory and practice of industrial pharmacy. Philadelphia: Lea and Febiger; 1991. p. 312–5.
Rudnic E, Schwartz JB. Oral solid dosage forms. In: Hoover JE, editor. Remington’s pharmaceutical sciences. Easton: Mack; 1980. p. 1633–65.
Schwartz JW, Connors RE, Schnaare RL. Optimization techniques in pharmaceutical formulation and processing. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics (Drugs and the pharmaceutical Sciences series). Marcel Dekker: Philadelphia; 2002. p. 607–26.
Grundy JS, Anderson KE, Rogers JA, Foster RT. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro test. J Control Release. 1997;48:1–8.
Liu X, Chen D, Zhang R. Evaluation of monolithic osmotic tablet system for nifedipine delivery in vitro and in vivo. Drug Develop Ind Pharm. 2003;29:813–9.
Lu EX, Zhi-Jiang ZQ. A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent. J Control Release. 2000;92:375–82.
Thombre AG, Appel LE, Chidlaw MB. Osmotic drug delivery using swellable-core technology. J Control Release. 2004;94:75–89.
Cardinal JR, Herbig SM, Korsmeyer RW, Smith KL, Thombre AG. Use of asymmetric membranes in delivery devices US Patent 5612059 1997.
Makhija SN, Vavia PR. CPOP-based controlled release systems for psedoephedrine-I, cellulose acetate as a semipermeable membrane. J Control Release. 2003;89:5–18.
Acknowledgment
The authors are thankful to Sekhsaria Chemicals Pvt. Ltd. for support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhanushali, R., Wakode, R. & Bajaj, A. Monolithic Osmotic Tablets for Controlled Delivery of Antihypertensive Drug. J Pharm Innov 4, 63–70 (2009). https://doi.org/10.1007/s12247-009-9055-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12247-009-9055-5